# Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

> **NCT05512416** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 35 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** dalpiciclib plus letrozole

## Key facts

- **NCT ID:** NCT05512416
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08
- **Primary completion:** 2023-08
- **Final completion:** 2024-05
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512416, "Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05512416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*